Last reviewed · How we verify
NCT05939310: MARGIN-2
Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 Study
NA trial testing Fluorescence guided detection of tumor positive margins. in Breast Cancer in 70 participants. Currently enrolling.
30 September 2024
Quick facts
| Lead sponsor | University Medical Center Groningen |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 70 |
| Start date | 1 January 2024 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 2 locations across Netherlands |
Drugs / interventions tested
- Fluorescence guided detection of tumor positive margins.
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Cancer Invasive — all drugs for Breast Cancer Invasive →
Sponsor
University Medical Center Groningen
Who can join
18 and older, female only, with Breast Cancer or Breast Cancer Invasive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to intraoperatively visualize tumour tissue in breast cancer patients using fluorescence imaging with the tracer bevacizumab-IRDye800CW and thereby enhance real-time clinical decision making, preventing postoperative tumour-positive margins.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current clinical applications of Cerenkov luminescence for intraoperative molecular imaging.
Boykoff N, Grimm J. · · 2024 · cited 6× · PMID 38243119 · DOI 10.1007/s00259-024-06602-3
Verify or expand the search:
- PubMed search for NCT05939310
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University Medical Center Groningen trials
Trials by the same sponsor.
- NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
- NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
- NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
- NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
- NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05939310 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
- Last refreshed: 19 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939310.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing